JPH11113531A - Health food - Google Patents
Health foodInfo
- Publication number
- JPH11113531A JPH11113531A JP9320233A JP32023397A JPH11113531A JP H11113531 A JPH11113531 A JP H11113531A JP 9320233 A JP9320233 A JP 9320233A JP 32023397 A JP32023397 A JP 32023397A JP H11113531 A JPH11113531 A JP H11113531A
- Authority
- JP
- Japan
- Prior art keywords
- himematsutake
- mannan polysaccharide
- health food
- xylose
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、腫瘍を発症した患者、
または腫瘍の発生に対する免疫力を高めようとする人に
適する健康食品を提供せんとするもので、健康食品を使
用するもの、また、健康食品製造業や健康食品の提供を
業とする者の利点に関する。The present invention relates to a patient having developed a tumor,
Or to provide health foods suitable for those who are trying to increase immunity against tumor development, using health foods, and benefits of those who are engaged in health food manufacturing and health food provision About.
【0002】[0002]
【従来の技術】固型癌や腫瘍を治療中の人、またはこれ
等を予防しようとする人に向いた健康食品が幾つか知ら
れている。例えば下記の諸報文等により、ハラタケ属に
属するヒメマツタケ(和名:カワリハラタケ、学名:ア
ガリクス ブラゼイ ムリル)の菌糸体、または子実体
を溶媒で抽出した多糖体(製法は例えば特公昭61−4
7518)が抗腫瘍効果や予防効果を有することは知ら
れており、これを用いた健康食品も製造されている。2. Description of the Related Art Several health foods are known for those who are treating solid cancers and tumors or those who are trying to prevent them. For example, a polysaccharide obtained by extracting the mycelium or fruiting body of Himematsutake (Japanese name: Kawariharatake, Scientific name: Agaricus brazeimuryl) belonging to the genus Agaricus with a solvent according to the following reports, etc.
7518) is known to have an antitumor effect and a preventive effect, and health foods using the same are also manufactured.
【0003】・「ヒメマツタケ由来・抗腫瘍性多糖体に
よる細網内皮系機能の活性化」…(医学と生物学、10
9巻、第5号)"Activation of reticuloendothelial system function by antitumor polysaccharide derived from Himematsutake mushroom" (medicine and biology, 10
Volume 9, Issue 5)
【0004】・「ヒメマツタケ脂質画分の抗癌活性とマ
クロファージ活性」…(同上誌、第112巻、第1号)"Anti-cancer activity and macrophage activity of lipid fraction of Himematsutake mushroom" ... (ibid., Vol. 112, No. 1)
【0005】・「ヒメマツタケ由来多糖体の前投与によ
るハツカネズミ Sarcoma−180固型癌に対す
る抗腫瘍効果」…(同上誌、第114巻、第4号)"Anti-tumor effect on Mus musculus Sarcoma-180 solid cancer by pre-administration of polysaccharide derived from Himematsutake" (ibid., Vol. 114, No. 4)
【0006】・「細網内皮系活性作用よりみたヒメマツ
タケの経目投与による投与スケジュールの検討」…(同
上誌、第127巻、第4号)-"Study on administration schedule by eye administration of Himematsutake from the viewpoint of reticuloendothelial system activity" (ibid., Vol. 127, No. 4)
【0007】・「ヒメマツタケAgaricus bl
azei (岩出101株)より分離した新規多糖−タ
ンパク複合体(ATOM)の担ガンマウスにおける抗腫
瘍効果とその作用機作…(ANTICANCER RE
SEARCH、第17巻)[Himematsutake Agaricus bl]
antitumor effect in cancer-bearing mice of a novel polysaccharide-protein conjugate (ATOM) isolated from Azei (Iwade 101 strain) and its mechanism of action ... (ANTICANCER RE
SEARCH, Vol. 17)
【0008】また、主鎖にキシロース、側鎖にアラビノ
ース重合体を有する変性ヘミセルロース含有物は米糠の
ヘミセルロースを基質として用い、茸由来の複数の炭水
化物分解酵素を反応させることにより得られる変性ヘミ
セルロースを主な成分とし、その化学構造は化1に示す
ように、主鎖にキシロース、側鎖にアラビノースの重合
体を有するアラビノキシランであり、既に健康食品とし
て用いられている。The modified hemicellulose containing xylose in the main chain and arabinose polymer in the side chain is mainly composed of denatured hemicellulose obtained by reacting a plurality of carbohydrate-degrading enzymes derived from mushrooms using rice bran hemicellulose as a substrate. It is an arabinoxylan having a polymer of xylose in the main chain and arabinose in the side chain as shown in Chemical formula 1, and is already used as a health food.
【0009】[0009]
【化1】 Embedded image
【0010】この効果については「ABSTRACT
BOOK MGN−3(Arabinoxylane
Compound)」等で既に公知となっている。[0010] This effect is described in "ABSTRACT".
BOOK MGN-3 (Arabinoxylane)
Compound)).
【0011】更に、乳酸菌の1種、ラクトバチルス ブ
レービス サブスピーシーズ コアグランスを高濃度
(5億/g)で含有する健康食品が発売されており、そ
の効能については「ラブレ菌のINF−α産生能への影
響」(京都パストゥール研究所研究報告’94.5・6
号)や「ラクトバシラス・ブレビス(ラブレ)菌の機能
とその利用」(食品と開発、第29巻、第8号)等で公
知となっており、当該菌含有物そのものは特許も取得し
ている(特許第2051579)。しかし、これ等の各
素材の健康食品の機能をもってしても、固型癌や腫瘍を
持つ患者または肺瘍の発生を抑制せんとする人への効能
は十分と言うには遠く、より高い効能を持つ食品の出現
が待たれていた。Furthermore, health foods containing a high concentration (500 million / g) of Lactobacillus brevis subspecies coagulans, one of the lactic acid bacteria, have been put on the market. Impact of Kyoto Pasteur Institute Research Report '94 .5.6
No.) and "Functions and Uses of Lactobacillus brevis (Labre) Bacteria" (Food and Development, Vol. 29, No. 8), etc., and the bacteria-containing substance itself has been patented. (Japanese Patent No. 2051579). However, even with the health food function of each of these ingredients, the efficacy for patients with solid cancer or tumors or those who want to suppress the development of lung ulcers is far from sufficient, and higher efficacy The appearance of foods with has been awaited.
【0012】[0012]
【発明が解決しようとする課題】上述のように、これま
でさまざまな健康食品が固型癌や腫瘍を持つ患者または
腫瘍の発生を抑制せんとする人のために市販されて来て
いるが、その機能は十分でなく、少しでもより高い効能
が求められており、上記の3素材も、個々では、十分な
抗癌・抗腫瘍効果または腫瘍の発生を予防・抑制する作
用を発揮することが出来なかった。これ等各健康食品を
混合して素材として使用すれば、各素材が本来的に持っ
ている機能を相乗的に発揮されることが予想されたが、
具体的な配合方法は未知であった。As described above, various health foods have been marketed for patients with solid cancer or tumors or for those who want to suppress the occurrence of tumors. Its function is not sufficient, and a slightly higher efficacy is required, and the above three materials can individually exert sufficient anticancer / antitumor effects or prevent / suppress the occurrence of tumor. I could not do it. It was expected that if these health foods were mixed and used as materials, the functions inherent in each material would be synergistically exhibited.
The specific compounding method was unknown.
【0013】[0013]
【課題を解決するための手段】請求項1に記載した構成
素材の有効成分のうち前二者、即ちヒメマツタケ由来マ
ンナン多糖体、及び主鎖にキシロース、側鎖にアラビノ
ース重合体を有する変性ヘミセルロースが癌の予防や直
接抗腫瘍効果を持つのに対し、後者即ち、ラクトバチル
ス ブレービス サブスピーシーズ コアグランスは摂
取者のインターフェロン産生能を高めることが主たる効
能であり、前二者と後者の間に、機能に少しニュアンス
がある。発明者らは前二者を混合する時の適正配合を実
験により特定した。更にこの混合物に、適正量の後者を
加えれば、インターフェロンの機能が加わり、従来の医
薬・健康食品では十分ではない、腫瘍の治療や癌・腫瘍
を含む病気への免疫・インターフェロンによる予防能力
を持つ、健康な身体をつくる上で大きな寄与をなすこと
になる。Means for Solving the Problems Of the active ingredients of the constituent material according to claim 1, the former two, namely, mannan polysaccharide derived from Himematsutake, and modified hemicellulose having xylose in the main chain and arabinose polymer in the side chain. While the latter, namely Lactobacillus brevis subspecies coagulans, has the main effect of increasing the interferon-producing ability of the ingestor, whereas the latter has a direct antitumor effect, it has a significant effect on the function between the former and the latter. There is a little nuance. The inventors have determined by experimentation the proper formulation for mixing the former two. Furthermore, if an appropriate amount of the latter is added to this mixture, the function of interferon will be added, and it will have the ability to treat tumors and immunize against diseases including cancer and tumors, and prevent it by interferon, which is not enough with conventional medicines and health foods And make a big contribution to building a healthy body.
【0014】発明者らは前二者、即ちヒメマツタケ由来
マンナン多糖体と主鎖にキシロース、側鎖にアラビノー
ス重合体を有する変性ヘミセルロースの混合物におい
て、ヒメマツタケ由来マンナン多糖体含有率を0%、2
5%、50%、75%、100%と変化させ、これを腫
瘍細胞、Sarcoma−180(以下S−180と略
称する)を移植したラット(ICR、雄、6〜8週齢)
に、S−180移植の10日前から、ラットの体重1k
g当り0.04g/日を経口投与して60日間観察し、
60日後の腫瘍の大きさを測定した。[0014] The inventors of the present invention, that is, in the mixture of mannan polysaccharide derived from Himematsutake and modified hemicellulose having xylose in the main chain and arabinose polymer in the side chain, the content of Mannan polysaccharide derived from Himematsutake was 0%,
Rats (ICR, male, 6-8 weeks old) transplanted with tumor cells, Sarcoma-180 (hereinafter abbreviated as S-180), which were changed to 5%, 50%, 75%, and 100%.
From 10 days before S-180 transplantation, rats weigh 1k
0.04 g / g / g was orally administered and observed for 60 days,
After 60 days, the size of the tumor was measured.
【0015】その結果、表1、表2、表3、表4及び表
5に示すようにヒメマツタケ由来マンナン多糖体0%の
時の平均発生腫瘍面積と各場合のそれとを比較した時、
ヒメマツタケ由来マンナン多糖体含有率25%〜75%
に於て、95%以上の信頼度をもって発生率が少ないと
いう帰無仮説が成り立つことが判った。As a result, as shown in Table 1, Table 2, Table 3, Table 4, and Table 5, when the average tumor area at 0% of the mannan polysaccharide derived from Himematsutake was compared with that in each case,
Mannan polysaccharide content from Himematsutake 25% to 75%
It was found that the null hypothesis that the incidence was low with a reliability of 95% or more was established.
【0016】[0016]
【表1】 [Table 1]
【0017】[0017]
【表2】 [Table 2]
【0018】[0018]
【表3】 [Table 3]
【0019】[0019]
【表4】 [Table 4]
【0020】[0020]
【表5】 [Table 5]
【0021】この解析には表1に示したような、推計学
的解析方法を用い、配合比を変えた各場合の計算結果は
表2、表3、表4及び表5に示した。これ等をまとめる
と図1のようになり、判断基準を95%の信頼度とすれ
ば、図1でデータを外挿予測すれば、ヒメマツタケ由来
マンナン多糖体含有率は20%程度でも効果が期待でき
る。In this analysis, a stochastic analysis method as shown in Table 1 was used, and calculation results in each case where the mixing ratio was changed are shown in Tables 2, 3, 4 and 5. These results are summarized in Fig. 1. If the judgment criterion is assumed to be 95% reliability, extrapolation and prediction of the data in Fig. 1 is expected to have an effect even if the mannan polysaccharide content from Himematsutake is about 20%. it can.
【0022】更に前二者に、抗原が体内に入ると抗体が
できて、一般の免疫作用が発現されるまでの間、身体を
保護する作用のある、インターフェロンの産生能を高め
るラクトバチルス ブレービス サブスピーシーズ コ
アグランス含有物を混合したものは、健康食品として当
然優れた効果が発現されることになる。[0022] Further, the former two groups are described as follows. Antibodies are formed when an antigen enters the body, and until the general immunity is manifested, Lactobacillus brevis subs that enhances the ability to produce interferon, which protects the body. Naturally, a mixture of the species containing coagulans will exhibit an excellent effect as a health food.
【0023】[0023]
【実施例】実施したラットによる実験では、ラットの体
重1kg当り0.04gのヒメマツタケ由来マンナン多
糖体と、主鎖にキシロース、側鎖にアラビノース重合体
を有する変性ヘミセルロースの混合物を投与したが、人
間の体重を平均60kgとしてこれを一日分の投与量と
すれば、2.4g/日が投与量になる。しかし、ラット
と人間との違いを考慮してこれよりは多く、また、配合
効果を考慮して、従来、各素材が投与の目安として来た
5〜6g/日よりは少ない量の、4.5g/日程度を目
安にできる。これに、ラクトバチルス ブレービス サ
ブスピーシーズ コアグランスを、従来の摂取量の目安
である3億/日を加える製品などが、健康食品として望
ましい。In the experiment with rats, a mixture of 0.04 g of mannan polysaccharide derived from Himematsutake and modified hemicellulose having xylose in the main chain and arabinose polymer in the side chain was administered per kg of the rat. Assuming that the body weight of an animal is 60 kg on average and this is the daily dose, the dose is 2.4 g / day. However, in consideration of the difference between rats and humans, the amount is higher than this, and in consideration of the combination effect, the amount of each material is less than 5-6 g / day, which is conventionally used as a guideline for administration of each material. It can be about 5 g / day. Lactobacillus brevis subspecies coagulans, which is a conventional health food, is preferably a product in which conventional intake amount of 300 million / day is added.
【0024】[0024]
【実施例】健康食品の製造コストの内、混合工程の費用
は大きい。特に、材料が顆粒や錠剤同士であれば、混合
のために粉砕工程が加わるので、コストは非常に大きく
なる。当該の3素材、即ちヒメマツタケ由来マンナン多
糖体含有物、及び主鎖にキシロース、側鎖にアラビノー
ス重合体を有する変性ヘミセルロースを含有する物質、
そしてラクトバチルス ブレービス サブスピーシーズ
コアグランス含有物はそれぞれ、粉体、液体、顆粒、
錠剤での供給が可能であるが、発明者らは混合コストを
下げて、より廉価に商品化することを意図し、素材の形
態を定めるために小試験(混合に要する時間測定)を行
なった。その結果、混合コストが最も下がるのは、最も
速やかに均一に混合した、3素材とも液体の場合であ
り、3素材の内、2素材を液体で供給し、これに粉体で
供給した他の1素材を加えてブレンドする場合がこれに
次ぐことが判った。DESCRIPTION OF THE PREFERRED EMBODIMENTS Among the manufacturing costs of health foods, the cost of the mixing step is large. In particular, if the material is granules or tablets, a pulverizing step is added for mixing, so that the cost becomes extremely large. A material containing a modified hemicellulose having xylose in the main chain and an arabinose polymer in the side chain;
And the Lactobacillus Brevis subspecies coagulans content is powder, liquid, granule,
Although tablets can be supplied, the inventors conducted a small test (measurement of the time required for mixing) to determine the form of the material, with the intention of lowering the mixing cost and commercializing at a lower cost. . As a result, the lowest mixing cost is obtained when the three materials, which are the most rapidly and uniformly mixed, are all liquids. Of the three materials, two materials are supplied as liquids, and the other materials are supplied as powders. It was found that the case where one material was added and blended was next to this.
【0025】[0025]
【実施例】また、1素材をエキスで供給して他の2素材
を粉体とした場合、3素材とも粉体で供給するよりも混
合に時間が掛かることが判った。実際の市場では素材が
液体で全て供給されるとは限らないので、3素材とも粉
体を用いる可能性があるが、発明者らは3素材とも粉体
を用いることも実用上可能であることを確認した。EXAMPLES It was also found that when one raw material was supplied as an extract and the other two raw materials were powdered, the mixing time was longer for all three raw materials than when they were supplied as powders. In the actual market, all the materials are not necessarily supplied as liquids, so there is a possibility that all three materials use powder. However, the inventors have found that it is practically possible to use powder for all three materials. It was confirmed.
【0026】[0026]
【発明の効果】ヒメマツタケ由来マンナン多糖体含有
物、及び主鎖にキシロース、側鎖にアラビノース重合体
を有する変性ヘミセルロースの含有物の混合物におい
て、各素材の有効成分の重量の比率において、前者を2
0%〜75%の範囲で含有する素材と、この2素材の混
合物の有効成分4.5g当り、ラクトバチルス ブレー
ビスサブスピーシーズ コアグランスを3億以上含有す
る素材を混合した本発明による、健康食品を摂取するこ
とにより、従来からある各素材の健康食品に比べて、抗
腫瘍効果、インターフェロンによる効果が発揮され、よ
り優れた抗腫瘍効果や腫瘍発生予防作用をもたらすこと
ができる。In the mixture of the mannan polysaccharide-containing material derived from Himematsutake and the modified hemicellulose containing xylose in the main chain and arabinose polymer in the side chain, the weight ratio of the active ingredient of each material is 2%.
A health food according to the present invention comprising a mixture of a material containing 0% to 75% and a material containing 300 million or more Lactobacillus brevis subspecies coagulans per 4.5 g of the active ingredient of a mixture of the two materials. By ingestion, the antitumor effect and the effect of interferon are exerted as compared with conventional health foods of each material, and a more excellent antitumor effect and a preventive effect against tumor development can be brought about.
【0027】また、配合する各素材、ヒメマツタケ由来
マンナン多糖体含有物と、主鎖にキシロース、側鎖にア
ラビノース重合体を有する変性ヘミセルロースの含有
物、及びラクトバチルス ブレービス サブスピーシー
ズ コアグランス含有物の全てが液体であるか、2素材
は液体で他は粉体であるか、または3素材とも粉体で供
給し混合する本発明により、廉価でこの健康食品を市場
に出すことが可能となる。Further, each of the ingredients to be blended, the mannan polysaccharide-containing material derived from Himematsutake, the modified hemicellulose containing xylose in the main chain and the arabinose polymer in the side chain, and the Lactobacillus brevis subspecies coagulans-containing material are all contained. The present invention in which the liquid is liquid, the two raw materials are liquid and the others are powder, or the three raw materials are supplied and mixed with the powder, makes it possible to market this health food at low cost.
【図1】実験結果(ヒメマツタケ由来マンナン多糖体と
主鎖にキシロース、側鎖にアラビノース重合体を有する
変性ヘミセルロースとの配合比率と、S−180を移植
したラットに生じた腫瘍の面積との関係)である。BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the relationship between the mixing ratio of mannan polysaccharide derived from Himematsutake and modified hemicellulose having xylose in the main chain and arabinose polymer in the side chain, and the area of the tumor formed in the S-180-transplanted rat. ).
Claims (3)
び、主鎖にキシロース、側鎖にアラビノース重合体を有
する変性ヘミセルロースの含有物との混合物を、両者の
有効成分、即ちヒメマツタケ由来マンナン多糖体及び、
主鎖にキシロース、側鎖にアラビノース重合体を有する
変性ヘミセルロースの合計重量につき、重量比で、ヒメ
マツタケ由来マンナン多糖体を20%〜75%の範囲で
含有させて作った混合物の有効成分4.5g当り、乳酸
菌の一種であるラクトバチルスブレービス サブスピー
シーズ コアグランスを3億以上を含むラクトバチルス
ブレービス サブスピーシーズ コアグランス含有物
を混合して成ることを特徴とする健康食品。1. A mixture of a mannan polysaccharide containing Himematsutake and a modified hemicellulose having xylose in the main chain and an arabinose polymer in the side chain, a mixture of the active ingredients of both, namely, a mannan polysaccharide derived from Himematsutake,
4.5 g of an active ingredient of a mixture prepared by containing 20% to 75% of mannan polysaccharide derived from Himematsutake by weight based on the total weight of modified hemicellulose having xylose in the main chain and arabinose polymer in the side chain. A health food comprising a mixture of Lactobacillus bravis subspecies coagulans containing at least 300 million Lactobacillus bravis subspecies coagulans, which is a kind of lactic acid bacteria.
マツタケ由来マンナン多糖体含有物と、主鎖にキシロー
ス、側鎖にアラビノース重合体を有する変性ヘミセルロ
ースの含有物、及びラクトバチルス ブレービス サブ
スピーシーズコアグランス含有物の全てが液体である
か、2素材は液体、他は粉体であることを特徴とする、
健康食品。2. The ingredients according to claim 1, wherein the ingredients include a mannan polysaccharide containing Himematsutake, a modified hemicellulose having xylose in the main chain and an arabinose polymer in the side chain, and Lactobacillus brevis subspecies core. Wherein all of the glance contents are liquid or two materials are liquid, and the other is powder,
healthy food.
とも、それぞれ粉体であることを特徴とする健康食品。3. The health food according to claim 1, wherein each of the three ingredients is a powder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9320233A JPH11113531A (en) | 1997-10-17 | 1997-10-17 | Health food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9320233A JPH11113531A (en) | 1997-10-17 | 1997-10-17 | Health food |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11113531A true JPH11113531A (en) | 1999-04-27 |
Family
ID=18119219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9320233A Pending JPH11113531A (en) | 1997-10-17 | 1997-10-17 | Health food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH11113531A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002338475A (en) * | 2001-05-14 | 2002-11-27 | Nippon Shokuhin Kako Co Ltd | Antitumor composition |
KR20020089149A (en) * | 2001-05-21 | 2002-11-29 | 콤비 가부시키가이샤 | Infection-preventing composition, and food or drink containing the same |
WO2004004748A1 (en) * | 2002-07-02 | 2004-01-15 | Kyowa Engineering Co., Ltd. | Agaricus blazei murill extract capable of preventing cancer induction or metastasis |
JP5881118B2 (en) * | 2010-08-25 | 2016-03-09 | 学校法人 関西大学 | Ice crystallization inhibitor from basidiomycetes |
-
1997
- 1997-10-17 JP JP9320233A patent/JPH11113531A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002338475A (en) * | 2001-05-14 | 2002-11-27 | Nippon Shokuhin Kako Co Ltd | Antitumor composition |
KR20020089149A (en) * | 2001-05-21 | 2002-11-29 | 콤비 가부시키가이샤 | Infection-preventing composition, and food or drink containing the same |
WO2004004748A1 (en) * | 2002-07-02 | 2004-01-15 | Kyowa Engineering Co., Ltd. | Agaricus blazei murill extract capable of preventing cancer induction or metastasis |
JPWO2004004748A1 (en) * | 2002-07-02 | 2005-11-04 | 協和エンジニアリング株式会社 | Kawariharatake extract prevents cancer induction or cancer metastasis |
US7611715B2 (en) | 2002-07-02 | 2009-11-03 | Ssi Co., Ltd. | Agaricus extract for preventing the induction or metastasis of cancer |
JP4823519B2 (en) * | 2002-07-02 | 2011-11-24 | 協和発酵バイオ株式会社 | Kawariharatake extract prevents cancer induction or cancer metastasis |
JP5881118B2 (en) * | 2010-08-25 | 2016-03-09 | 学校法人 関西大学 | Ice crystallization inhibitor from basidiomycetes |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Choi et al. | Aqueous extract isolated from Platycodon grandiflorum elicits the release of nitric oxide and tumor necrosis factor-α from murine macrophages | |
Kodama et al. | Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells | |
EP0183556B1 (en) | Use of chitin- or chitosan-oligomers for the manufacture of a immunopotentiating agent for enhancing the immune response against bacterial and fungal infections and against the growth of tumours | |
JP4667568B2 (en) | Immune enhancing composition | |
JP3621404B1 (en) | Immunity enhancing active agent | |
IT8922725A1 (en) | USE OF IMMUNOMODULANTS AS SYNERGIC AGENTS OF CHEMOTHERAPY IN CANCER THERAPY | |
KR20070054222A (en) | Medicine having analgesic effects | |
Ha et al. | The effect of vitamin B6 deficiency on cytotoxic immune responses of T cells, antibodies, and natural killer cells, and phagocytosis by macrophages | |
US6255291B1 (en) | Composition and method for treating cancer and immunological disorders resulting in chronic conditions | |
JPH10139670A (en) | Interleukin 12 inducer and pharmaceutical composition | |
JPH11113531A (en) | Health food | |
JP2003137790A (en) | Medicine including fructooligosaccharide including beta-2, 1 (beta 2 -> beta 1) bond-chain fructose oligomer as active ingredient | |
JP2003183176A (en) | Immunopotentiating composition | |
Cassone et al. | Cell wall of Candida albicans and host response | |
US6464981B2 (en) | Therapeutic agent for a cancer and method of screening the same, and health-care auxiliary food | |
JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
US20040198696A1 (en) | Agent and food for inhibiting IgE antibody | |
CN105412155A (en) | Application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of chemotherapeutic drug combined with trichoderma pseudokoningii exopolysaccharide in treating colon cancer | |
JPH11152230A (en) | Composition containing mushroom or its extract | |
Ha | The inhibitory effect of the Chinese herb Ganoderma lucidum mycelium on gut immunoglobulin A responses to cholera toxin in mice | |
TWI224006B (en) | LAK activity potentiator orginating in shiitake mushroom hyphae extract and LAK activity potentiating preparations containing the same | |
CN115414343B (en) | Application of alpha-ketoglutaric acid and derivatives thereof and medicine for preventing and treating skin tumor | |
CN100346780C (en) | Compound preparation for prevention and treatment adiposis and its prepn. method | |
CN115845051B (en) | Pharmaceutical composition and pharmaceutical preparation and application thereof in treating liver cancer | |
Saijo et al. | Changes in serum erythropoietin levels during chemotherapy for lung cancer |